FDA Determines Regulatory Review Period for BAKSUPTM/SUP Interbody Fusion System Patent Extension Application

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for the BAKSUPTM/SUP Interbody Fusion System, a medical device, and is publishing this notice as required by law. The FDA made this determination due to a patent extension application submitted to the Commissioner of Patents and Trademarks, Department of Commerce, for this medical device.